Azenosertib
- Generic Name
- Azenosertib
- Drug Type
- Small Molecule
- Chemical Formula
- C29H34N8O2
- CAS Number
- 2376146-48-2
- Unique Ingredient Identifier
- 9J13XU96Z1
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Target Recruit Count
- 76
- Registration Number
- NCT04814108
- Locations
- 🇺🇸
Revive Clinical Research, Sterling, Michigan, United States
🇦🇺Concord Repatriation General Hospital, Concord, New South Wales, Australia
🇺🇸Alaska Women's Cancer Care, Anchorage, Alaska, United States
A Study of ZN-c3 in Patients With Ovarian Cancer
Phase 1
Recruiting
- Conditions
- Peritoneal CancerEpithelial Ovarian CancerFallopian Tube CancerSolid Tumor
- Interventions
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Target Recruit Count
- 140
- Registration Number
- NCT04516447
- Locations
- 🇦🇺
Site 2716, Melbourne, Victoria, Australia
🇺🇸Site 0264, Aurora, Colorado, United States
🇺🇸Site 0104, Boston, Massachusetts, United States
A Study of ZN-c3 in Participants With Solid Tumors
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Target Recruit Count
- 146
- Registration Number
- NCT04158336
- Locations
- 🇺🇸
Site 0102, Tucson, Arizona, United States
🇺🇸Site 0103, Houston, Texas, United States
🇺🇸Site 0179, Pittsburgh, Pennsylvania, United States
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Early Phase 1
Recruiting
- Conditions
- Locally Advanced Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Metastatic Pancreatic Ductal AdenocarcinomaStage III Pancreatic Cancer AJCC v8Unresectable Pancreatic Ductal AdenocarcinomaBorderline Resectable Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 90
- Registration Number
- NCT04005690
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath